YWYue Wang

Yue Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yue Wang has a total of 115 co-authors. Here are the top co-authors by number of shared publications:

  • H. Eric Xu

    CAS Key Laboratory of Receptor Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

    11 shared publications
  • Youwen Zhuang

    School of Medicine, Shanghai Jiao Tong University

    8 shared publications
  • Kai Wu

    State Key Laboratory of Drug Research. Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

    6 shared publications
  • Qingning Yuan

    The State Key Laboratory of Drug Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

    6 shared publications
  • Wen Hu

    The State Key Laboratory of Drug Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

    5 shared publications
  • Youwei Xu

    The State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

    5 shared publications

Latest Publications

  • Multiple allosteric sites allow for synergistic enhancement of GPCR signaling

    by Kai Wang, Snezana T. Dimova, John N. Hanson, Abhishek Thakur, Youwei Xu, Yini Liu, Amy E. Moritz, Alexander Goldberg, Bing Xie, Jayachandra Rayadurgam, et al.

    Allosteric modulation of G protein–coupled receptors (GPCRs) offers promising therapeutic opportunities. Although multiple allosteric binding sites have been identified in GPCRs, whether and how these spatially distinct sites cooperate to regulate receptor activation remain poorly understood. Here, we elucidate the molecular mechanism of cooperative multisite allostery in the dopamine D1 receptor (D1R). We developed two novel D1R positive allosteric modulators (PAMs), UNC9815 and UNC10062, and used cryo–electron microscopy to structurally identify two previously uncharacterized D1R allosteric sites occupied by UNC9815/UNC10062 and another D1R PAM, BMS-A1. Both sites localize to the transmembrane helix (TM) 1 to 7 interface as vertically adjacent allosteric pockets organized in a spatially complementary manner. Our structures demonstrate the simultaneous binding of the chemically distinct PAMs (LY3154207, BMS-A1, and UNC9815/UNC10062) in three nonoverlapping pockets. Concurrent engagement of all three allosteric sites produces pronounced functional cooperativity, increasing dopamine potency by >1000-fold, thereby demonstrating that coordinated multisite modulation can achieve substantial pharmacological amplification beyond the limits imposed by single PAM administration. Molecular dynamics (MD) simulations revealed that multisite PAM engagement restricts intracellular loop 3 dynamics and stabilizes the TM7-NPxxY activation motif, effects not achieved by binding of LY3154207 alone, thereby biasing the receptor toward a more stabilized active conformation, and may also improve agonist potency by stabilizing extracellular loop 2. Together, these findings establish the structural framework for cooperative multisite allostery in a GPCR, revealing how distributed allosteric sites act in concert to amplify receptor activation and providing a conceptual foundation for developing innovative GPCR allosteric therapeutics.

  • Structural basis for dual targeting of μ-opioid and nociceptin/orphanin FQ receptors by Cebranopadol

    by Ya-Li Lai, Xin-Yi Huang, Shi-Yi Shen, Wen Hu, H. Eric Xu, Yue Wang

    Cebranopadol is a first-in-class analgesic that combines agonism at the μ-opioid receptor (μOR) and the nociceptin/orphanin FQ receptor (NOPR), an approach proposed to improve the therapeutic index of opioid analgesia. Although Cebranopadol is highly potent at both μOR and NOPR, the structural basis by which a single small molecule productively engages these two opioid-family receptors has remained unclear. Here, we report cryo-electron microscopy structures of Cebranopadol bound to human μOR–Gi and NOPR–Gi complexes at 2.95 Å and 2.74 Å resolution, respectively. In both receptors, Cebranopadol adopts a conserved orthosteric recognition mode anchored by the canonical D3.32–tertiary amine interaction, whereas local differences in the extracellular pocket shift ligand position to accommodate receptor-specific microenvironments. Combined with functional mutagenesis and molecular dynamics simulations across the opioid receptor family, these structures identify nonconserved pocket features at positions 2.63 and 7.35 that contribute to potency and selectivity by modulating fluorophenyl-directed interactions and hydrophobic packing around the spiroindole moiety. Together, these findings define a structural framework for understanding the dual agonism of Cebranopadol at μOR and NOPR and provide a working model for improving selectivity over δOR and κOR while preserving the desired dual-target pharmacology.

  • Open Access

    Structural characterization of kappa-opioid receptor dimer in complex with two G proteins

    by Yuxi Zhao, Chanjuan Xu, Yue Wang, Hong Shan, Jing Wang, Yuxuan Liu, Xin Luo, Junrui Li, Mingyang Li, Yini Liu, et al.

    The κ-opioid receptor (κOR) represents a promising non-addictive analgesic target due to its critical role in pain and reward pathways. Despite evidence of κOR dimerization, its molecular basis and pharmacological significance remain elusive. Here, we demonstrate stable κOR dimer formation in living cells and present cryo-electron microscopy structures of salvinorin A-bound κOR dimer complexed with two Gi proteins, revealing a parallel assembly distinct from previously characterized GPCR dimers that engage only single G protein. Multiple membrane lipids are positioned at the TM1-Helix 8 interface, where they make extensive contacts with both protomers and may contribute to the stability of the κOR dimer. Importantly, dimerization significantly enhances Gi protein recruitment to κOR in both potency and efficacy. We also demonstrate that salvinorin A, a non-nitrogenous agonist, binds similarly in monomeric and dimeric κOR, and identify Y3127.35 as a critical selectivity determinant across opioid receptors. These findings expand our understanding of opioid receptor pharmacology and signaling, providing a foundation for developing superior κOR-targeted therapeutics for pain and related disorders.


  • Open Access

    Rational design of a Kappa opioid receptor peptide agonist with attenuated β-arrestin signaling

    by Huanhuan Zhang, Ruolan Wang, Pan Shi, Gaoming Wang, Qingjun Zhu, Xinheng He, Youwei Xu, Qingning Yuan, Wen Hu, Kai Wu, et al.

    Difelikefalin is an FDA-approved κ-opioid receptor (KOR) peptide agonist used to treat chronic pruritus. However, as a balanced agonist that activates both G protein and β-arrestin pathways, difelikefalin remains associated with undesirable side effects linked to β-arrestin signaling. Here, we report the cryo-EM structure of the difelikefalin-KOR-Gi complex, identifying Y320 7.43 as a key residue that is critical for signaling bias. Guided by this structural insight, we engineer beta01, a β-amino acid-substituted analog with potent G protein activation but minimal β-arrestin recruitment. In mouse models, beta01 retains robust antinociceptive and antipruritic efficacy while significantly reducing sedation and anxiety-like behaviors. Structural, molecular dynamics simulations and 2D 13 C-Met NMR analyses further reveal beta01 stabilizes a unique KOR conformation with an expanded intracellular cavity that disfavors β-arrestin binding. This work establishes a rational structure-based framework for designing safer and more effective GPCR-targeted therapeutics.


  • Top Cited Papers
    Open Access

    Structure-based design of an opioid receptor modulator for enhanced morphine analgesia

    by Yue Wang, Ping Luo, Haiyan Xu, Li Zhan, Kensuke Sakamoto, Mingyu Li, Jing Wang, Xi-Ping Huang, Jianhui Zhou, Tao Liu, et al.

    The alarming rates of deaths due to opioid overdose present an urgent need for safer opioid analgesics. Positive allosteric modulators (PAMs) of opioid receptors (ORs) offer a promising approach to enhance opioid efficacy while reducing risks of overdose. In this study, we unveil the selective mechanism of PAM modulation of the OR family through structure elucidation of the δ-opioid receptor and μ-opioid receptor (μOR) bound to orthosteric agonists and PAMs BMS986187 (BMS187) and BMS986122 (BMS122). In addition, we uncovered an unexpected but conserved allosteric site across the transmembrane helices TM2 to TM4 of ORs, occupied by BMS187 but not BMS122. Leveraging these structural insights, we designed 9-(5-(4-chlorophenyl)furan-2-yl)-3,3,6,6-tetramethyl-3,4,5,6,7,9-hexahydro-1 H -xanthene-1,8(2 H )-dione (MPAM-15), whose αβ cooperativity factor is 33-fold higher than BMS122 and threefold higher than BMS187, indicating markedly stronger positive allosterism. Animal studies demonstrate that MPAM-15 shows excellent brain penetration and enhances morphine-induced antinociception without exacerbating respiratory depression or constipation. Molecular dynamics simulations revealed that MPAM-15 promotes and stabilizes the conformational equilibrium of μOR toward the canonical active state, providing a mechanistic basis for its enhanced allosteric potency. These discoveries substantially advance our understanding of OR allosteric mechanism and pave the way for the structure-based development of allosteric opioid analgesics.


  • Molecular recognition of two approved drugs Macimorelin and Anamorelin by the growth hormone secretagogue receptor

    by Ruo-Lan Wang, Jun Sun, Heng Liu, Shi-Meng Guo, Yu Zhang, Wen Hu, Jiang Wang, Hong Liu, You-Wen Zhuang, Yi Jiang, et al.

    The growth hormone secretagogue receptor (GHSR) plays a critical role in regulating growth hormone release and metabolic homeostasis. Understanding the molecular mechanisms of ligand-GHSR recognition is essential for developing therapeutic interventions. In this study, we investigated the molecular recognition mechanisms of two clinically approved drugs: Macimorelin (used for diagnosing adult growth hormone deficiency) and Anamorelin (approved in Japan for cancer cachexia). Using high-resolution cryo-electron microscopy, we determined the structures of GHSR bound to Macimorelin and Anamorelin in complex with Gq proteins at resolutions of 2.63 Å and 2.52 Å, respectively. We revealed that both drugs occupied a bifurcated binding pocket divided by a conserved salt bridge between E1243.33 and R2836.55. Through systematic mutagenesis and functional studies, we identified the key residues underlying the higher binding affinity of Anamorelin compared to Macimorelin. In addition, structural comparison of GHSR in complex with different G protein subtypes elucidated the mechanisms driving G protein selectivity. Our results provide crucial insights into GHSR-drug interactions and offer valuable guidance for designing more selective and potent GHSR agonists.

  • Open Access

    Structural insights into the agonist activity of the nonpeptide modulator JR14a on C3aR

    by Ping Luo, Wenwen Xin, Shimeng Guo, Xin Li, Qing Zhang, Youwei Xu, Xinheng He, Yue Wang, Wenjia Fan, Qingning Yuan, et al.


  • Open Access

    Selective ligand recognition and activation of somatostatin receptors SSTR1 and SSTR3

    by Yujue Wang, Youwei Xu, Yue Wang, Jie Zhang, Lan Chen, Xinheng He, Wenjia Fan, Kai Wu, Wen Hu, Xi Cheng, et al.

    Somatostatin receptors (SSTRs) exert critical biological functions such as negatively regulating hormone release and cell proliferation, making them popular targets for developing therapeutics to treat endocrine disorders, especially neuroendocrine tumors. Although several panagonists mimicking the endogenous ligand somatostatin are available, the development of more effective and safer somatostatinergic therapies is limited due to a lack of molecular understanding of the ligand recognition and regulation of divergent SSTR subtypes. Here, we report four cryoelectron microscopy structures of G i -coupled SSTR1 and SSTR3 activated by distinct agonists, including the FDA-approved panagonist pasireotide as well as their selective small molecule agonists L-797591 and L-796778. Our structures reveal a conserved recognition pattern of pasireotide in SSTRs attributed to the binding with a conserved extended binding pocket, distinct from SST14, octreotide, and lanreotide. Together with mutagenesis analyses, our structures further reveal the dynamic feature of ligand binding pockets in SSTR1 and SSTR3 to accommodate divergent agonists, the key determinants of ligand selectivity lying across the orthosteric pocket of different SSTR subtypes, as well as the molecular mechanism underlying diversity and conservation of receptor activation. Our work provides a framework for rational design of subtype-selective SSTR ligands and may facilitate drug development efforts targeting SSTRs with improved therapeutic efficacy and reduced side effects.


  • Open Access

    Molecular basis for the activation of PAF receptor by PAF

    by Wenjia Fan, Youwei Xu, Xinheng He, Ping Luo, Jingpeng Zhu, Junrui Li, Ruolan Wang, Qingning Yuan, Kai Wu, Wen Hu, et al.


  • Recognition of methamphetamine and other amines by trace amine receptor TAAR1

    by Heng Liu, You Zheng, Yue Wang, Yumeng Wang, Xinheng He, Peiyu Xu, Sijie Huang, Qingning Yuan, Xinyue Zhang, Ling Wang, et al.

    Trace amine-associated receptor 1 (TAAR1), the founding member of a nine-member family of trace amine receptors, is responsible for recognizing a range of biogenic amines in the brain, including the endogenous β-phenylethylamine (β-PEA)1 as well as methamphetamine (METH)2, an abused substance that has posed a severe threat to human health and society3. Given its unique physiological role in the brain, TAAR1 is also an emerging target for a range of neurological disorders including schizophrenia, depression and drug addiction2,4,5. Here we report structures of human TAAR1-G protein complexes bound to METH and β-PEA as well as complexes bound to RO5256390, a TAAR1 selective agonist, and SEP-363856, a clinical-stage dual agonist for TAAR1 and serotonin receptor 5-HT1AR6,7. Together with systematic mutagenesis and functional studies, the structures reveal the molecular basis of METH recognition and underlying mechanisms of ligand selectivity and polypharmacology between TAAR1 and other monoamine receptors. We identify a lid-like ECL2 helix/loop structure and a hydrogen-bonding network in the ligand binding pockets, which may contribute to the ligand recognition in TAAR1. These findings shed light on the ligand recognition mode and activation mechanism for TAAR1 and should guide the development of next-generation therapeutics for drug addiction and various neurological disorders.